Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States.

Autor: Armstrong AW; University of Southern California, Los Angeles, CA, USA., Patel M; AbbVie Inc, North Chicago, IL, USA., Li C; AbbVie Inc, North Chicago, IL, USA., Garg V; AbbVie Inc, North Chicago, IL, USA., Mandava MR; AbbVie Inc, North Chicago, IL, USA., Wu JJ; Department of Dermatology, University of Miami Miller School of Medicine, FL, USA.
Jazyk: angličtina
Zdroj: The Journal of dermatological treatment [J Dermatolog Treat] 2023 Dec; Vol. 34 (1), pp. 2200870.
DOI: 10.1080/09546634.2023.2200870
Abstrakt: Background: Switching therapies is common for patients with psoriasis.
Objective: To quantify real-world switching rates and characteristics among patients initiating biologics over 24 months.
Methods: Patients aged ≥18 years with ≥2 confirmed psoriasis diagnoses who initiated a new biologic were identified from a US-payer claims database (Merative® MarketScan®) Switching rates were reported over 24 months using Kaplan-Meier survival analysis, and multivariable Cox regression analyses were performed to identify associated patient characteristics.
Results: A total of 7997 patients were included, with overall treatment switch rates at 14.4% at 12 months and 26.0% at 24 months. IL-23 inhibitors were associated with the lowest risk of switching compared with TNF, IL-17, and IL-12/23 inhibitors over 24 months ( p  < 0.0001). Switch rates varied between specific biologics, with the lowest switch rates observed for patients treated with risankizumab at 8.5% followed by guselkumab at 15.7% over 24 months. Prior targeted immune modulator use, age, and female gender were predictors of switching (adjusted hazard ratio; 1.23, 1.31, and 1.40, respectively; p  ≤ 0.0005).
Limitations: Claims data may be subject to data errors and reasons for switching cannot be determined.
Conclusion: Switching was common in psoriasis patients using biologics over 24 months, with the lowest risk of switching observed with IL-23 inhibitors.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje